[go: up one dir, main page]

WO2013066374A3 - Humanin protection of dopaminergic neurons - Google Patents

Humanin protection of dopaminergic neurons Download PDF

Info

Publication number
WO2013066374A3
WO2013066374A3 PCT/US2012/000535 US2012000535W WO2013066374A3 WO 2013066374 A3 WO2013066374 A3 WO 2013066374A3 US 2012000535 W US2012000535 W US 2012000535W WO 2013066374 A3 WO2013066374 A3 WO 2013066374A3
Authority
WO
WIPO (PCT)
Prior art keywords
dopaminergic neurons
humanin
protection
disease
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/000535
Other languages
French (fr)
Other versions
WO2013066374A2 (en
Inventor
Radhika Muzumdar
Diana Casper
Rukmani LEKHRAJ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of WO2013066374A2 publication Critical patent/WO2013066374A2/en
Publication of WO2013066374A3 publication Critical patent/WO2013066374A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods are provided for treating Parkinson's disease, protecting dopaminergic neurons from neurotoxicity and for increasing DJ-1 levels in neruons. Methods are also provided for identifying candidate treatments for Parkinson's disease.
PCT/US2012/000535 2011-11-02 2012-11-02 Humanin protection of dopaminergic neurons Ceased WO2013066374A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554660P 2011-11-02 2011-11-02
US61/554,660 2011-11-02

Publications (2)

Publication Number Publication Date
WO2013066374A2 WO2013066374A2 (en) 2013-05-10
WO2013066374A3 true WO2013066374A3 (en) 2013-07-04

Family

ID=48192971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/000535 Ceased WO2013066374A2 (en) 2011-11-02 2012-11-02 Humanin protection of dopaminergic neurons

Country Status (1)

Country Link
WO (1) WO2013066374A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080440A1 (en) * 2022-10-12 2024-04-18 동아대학교 산학협력단 Composition for preventing or treating neurodegenerative disorders, comprising humanin peptide as active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233326A1 (en) * 2002-06-14 2005-10-20 Shuji Hinuma Novel screening method
US7371225B2 (en) * 2002-09-24 2008-05-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for convection enhanced delivery of therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233326A1 (en) * 2002-06-14 2005-10-20 Shuji Hinuma Novel screening method
US7371225B2 (en) * 2002-09-24 2008-05-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for convection enhanced delivery of therapeutic agents

Also Published As

Publication number Publication date
WO2013066374A2 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
MY169328A (en) Compositions for the treatment of dry eye
IL237369B (en) N-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3,-tetrafluoropropoxy)benzylamine in combination with an acetylcholinesterase inhibitor for treating alzheimer's disease
ZA201402049B (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2014058875A3 (en) Combination therapies and uses for treatment of demyelinating disorders
WO2012062925A3 (en) Compounds and methods for treating pain
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
WO2012174338A3 (en) Method of selecting therapeutic indications
TR201905683T4 (en) Ophthalmic formulation and method for erosive presbyopia.
WO2013056148A3 (en) Scd1 antagonists for treating cancer
IL231856A (en) 8-carbamoyl-2-(2,3-di substituted pyrid -6-yl)-1,2,3,4-tetrahydroisoquinoline derivatives as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EA201101521A1 (en) METHODS OF TREATMENT OF ONCOLOGICAL DISEASES, USING EPIMETABOLIC SWITCHES, MULTIPLE-DIFFERENT INTRACELLULAR MOLECULES OR IMPACT FACTORS
WO2012092320A3 (en) Eye treatment
WO2010118243A3 (en) Use of il-27 antagonists to treat lupus
MX2012000034A (en) Methods for treating or preventing fatigue.
WO2012173846A3 (en) Peptidomimetic macrocycles
WO2012135365A3 (en) Systems and methods for use in treating sensory impairment
EP4275750A3 (en) Treatment of alzheimer's disease in a particular patient population
WO2013040251A3 (en) Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2014004934A3 (en) Compositions and methods of treating alzheimer's disease
AU2012339701A8 (en) Autoclavable suspensions of cyclosporin A Form 2
HK1214517A1 (en) 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
WO2016103042A8 (en) Compositions and methods for inhibiting expression of adamts-5 and adam17
WO2013066374A3 (en) Humanin protection of dopaminergic neurons
WO2011123842A9 (en) Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12846677

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12846677

Country of ref document: EP

Kind code of ref document: A2